Multivariate risk factors for early (< 2 years after transplantation) and late (≥ 2 years) non-Hodgkin lymphoma during the first functioning transplant
| . | Early (n = 27)* . | Late (n = 79)† . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n . | PY . | IRR . | 95% CI . | P‡ . | n . | PY . | IRR . | 95% CI . | P‡ . | |
| Current age (single y)§ | 27 | 12746 | 1.01 | 0.98-1.04 | .453 | 79 | 35046 | 1.02 | 1.01-1.04 | .006 |
| Sex | ||||||||||
| Male | 16 | 7601 | 1.00 | 44 | 20589 | 1.00 | ||||
| Female | 11 | 5145 | 1.00 | 0.47-2.17 | .992 | 35 | 14457 | 1.09 | 0.70-1.70 | .710 |
| EBV IgG status at transplantation | ||||||||||
| Positive or unknown | 17 | 11314 | 1.00 | 74 | 32250 | 1.00 | ||||
| Negative | 10 | 1432 | 4.66 | 2.12-10.36 | <.001 | 5 | 2796 | 0.91 | 0.37-2.28 | .846 |
| Time since transplantation§ | ||||||||||
| Less than 1 y | 17 | 6758 | 1.00 | |||||||
| 1-1.99 y | 10 | 5988 | 0.66 | 0.30-1.44 | .295 | |||||
| 2-4.99 y | 12 | 14348 | 1.00 | |||||||
| 5-9.99 y | 43 | 13868 | 3.63 | 1.91-6.90 | <.001 | |||||
| 10-14.99 y | 20 | 5504 | 4.56 | 2.19-9.47 | ||||||
| 15 y or more | 4 | 1326 | 5.58 | 1.69-18.40 | ||||||
| Receipt of CNI (CyA, Tac)§ | ||||||||||
| No | 2 | 1635 | 1.00 | 10 | 8652 | 1.00 | ||||
| Yes | 25 | 11110 | 1.36 | 0.31-5.96 | .682 | 69 | 26394 | 3.13 | 1.53-6.39 | .002 |
| Receipt of antiproliferatives (Aza, MMF)§ | ||||||||||
| No | 6 | 1729 | 1.00 | 14 | 4963 | 1.00 | ||||
| Yes | 21 | 11016 | 0.50 | 0.17-1.23 | .120 | 65 | 30083 | 1.14 | 0.63-2.07 | .665 |
| Receipt of sirolimus§ | ||||||||||
| No | 26 | 12358 | 1.00 | |||||||
| Yes | 1 | 388 | 0.67 | 0.08-5.69 | .716 | |||||
| Receipt of T cell–depleting antibodies§ | ||||||||||
| No | 17 | 10120 | 1.00 | 59 | 26971 | 1.00 | ||||
| Yes | 10 | 2625 | 2.39 | 1.08-5.30 | .031 | 20 | 8075 | 1.21 | 0.37-2.28 | .846 |
| . | Early (n = 27)* . | Late (n = 79)† . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n . | PY . | IRR . | 95% CI . | P‡ . | n . | PY . | IRR . | 95% CI . | P‡ . | |
| Current age (single y)§ | 27 | 12746 | 1.01 | 0.98-1.04 | .453 | 79 | 35046 | 1.02 | 1.01-1.04 | .006 |
| Sex | ||||||||||
| Male | 16 | 7601 | 1.00 | 44 | 20589 | 1.00 | ||||
| Female | 11 | 5145 | 1.00 | 0.47-2.17 | .992 | 35 | 14457 | 1.09 | 0.70-1.70 | .710 |
| EBV IgG status at transplantation | ||||||||||
| Positive or unknown | 17 | 11314 | 1.00 | 74 | 32250 | 1.00 | ||||
| Negative | 10 | 1432 | 4.66 | 2.12-10.36 | <.001 | 5 | 2796 | 0.91 | 0.37-2.28 | .846 |
| Time since transplantation§ | ||||||||||
| Less than 1 y | 17 | 6758 | 1.00 | |||||||
| 1-1.99 y | 10 | 5988 | 0.66 | 0.30-1.44 | .295 | |||||
| 2-4.99 y | 12 | 14348 | 1.00 | |||||||
| 5-9.99 y | 43 | 13868 | 3.63 | 1.91-6.90 | <.001 | |||||
| 10-14.99 y | 20 | 5504 | 4.56 | 2.19-9.47 | ||||||
| 15 y or more | 4 | 1326 | 5.58 | 1.69-18.40 | ||||||
| Receipt of CNI (CyA, Tac)§ | ||||||||||
| No | 2 | 1635 | 1.00 | 10 | 8652 | 1.00 | ||||
| Yes | 25 | 11110 | 1.36 | 0.31-5.96 | .682 | 69 | 26394 | 3.13 | 1.53-6.39 | .002 |
| Receipt of antiproliferatives (Aza, MMF)§ | ||||||||||
| No | 6 | 1729 | 1.00 | 14 | 4963 | 1.00 | ||||
| Yes | 21 | 11016 | 0.50 | 0.17-1.23 | .120 | 65 | 30083 | 1.14 | 0.63-2.07 | .665 |
| Receipt of sirolimus§ | ||||||||||
| No | 26 | 12358 | 1.00 | |||||||
| Yes | 1 | 388 | 0.67 | 0.08-5.69 | .716 | |||||
| Receipt of T cell–depleting antibodies§ | ||||||||||
| No | 17 | 10120 | 1.00 | 59 | 26971 | 1.00 | ||||
| Yes | 10 | 2625 | 2.39 | 1.08-5.30 | .031 | 20 | 8075 | 1.21 | 0.37-2.28 | .846 |
PY and incident cancers during the first functioning transplant only; excludes 335 patients (n = 2 with late NHL) with incomplete data on immunosuppressive agents.
PY indicates person-years; IRR, incidence rate ratio; CI, confidence interval; CNI, calcineurin inhibitors; CyA, cyclosporine; Tac, tacrolimus; Aza, azathioprine; and MMF, mycophenolate.
Adjusted for current age, sex, EBV IgG status, time since transplantation, receipt of CNI, antiproliferative agents, sirolimus, and T cell–depleting antibodies.
Adjusted for current age, sex, EBV IgG status, time since transplantation, receipt of CNI, antiproliferative agents, and T cell–depleting antibodies.
P for homogeneity for categorical variables; P for trend for ordinal variables.
Time dependent; T cell–depleting antibodies Yes from time of first receipt.